Schroder Investment Management Group Buys 160,380 Shares of ICU Medical, Inc. $ICUI

Schroder Investment Management Group lifted its stake in ICU Medical, Inc. (NASDAQ:ICUI) by 25.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 796,704 shares of the medical instruments supplier’s stock after acquiring an additional 160,380 shares during the quarter. Schroder Investment Management Group owned approximately 3.23% of ICU Medical worth $93,246,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Inscription Capital LLC grew its stake in ICU Medical by 407.9% in the third quarter. Inscription Capital LLC now owns 8,365 shares of the medical instruments supplier’s stock valued at $1,003,000 after purchasing an additional 6,718 shares in the last quarter. Bryce Point Capital LLC bought a new stake in shares of ICU Medical during the 3rd quarter worth approximately $586,000. Federated Hermes Inc. boosted its holdings in shares of ICU Medical by 56.5% in the 3rd quarter. Federated Hermes Inc. now owns 290,292 shares of the medical instruments supplier’s stock valued at $34,823,000 after buying an additional 104,798 shares during the last quarter. Emerald Mutual Fund Advisers Trust acquired a new stake in shares of ICU Medical in the 3rd quarter valued at approximately $1,096,000. Finally, Aaron Wealth Advisors LLC bought a new position in shares of ICU Medical in the third quarter valued at $521,000. Institutional investors own 96.10% of the company’s stock.

Analyst Ratings Changes

ICUI has been the topic of a number of recent analyst reports. KeyCorp boosted their target price on shares of ICU Medical from $175.00 to $180.00 and gave the stock an “overweight” rating in a report on Friday, February 20th. Wall Street Zen upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Sunday, February 15th. Piper Sandler lifted their price objective on shares of ICU Medical from $172.00 to $178.00 and gave the company an “overweight” rating in a research report on Friday, February 20th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of ICU Medical in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $179.33.

ICU Medical Stock Up 1.0%

ICUI stock opened at $133.34 on Tuesday. ICU Medical, Inc. has a 1-year low of $107.00 and a 1-year high of $160.29. The business’s 50 day simple moving average is $148.93 and its 200 day simple moving average is $138.06. The company has a current ratio of 2.39, a quick ratio of 1.15 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $3.29 billion, a PE ratio of 6,670.34, a PEG ratio of 1.90 and a beta of 0.79.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Thursday, February 19th. The medical instruments supplier reported $1.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.68 by $0.23. ICU Medical had a return on equity of 7.33% and a net margin of 0.03%.The business had revenue of $535.94 million during the quarter, compared to the consensus estimate of $541.20 million. During the same quarter last year, the firm posted $2.11 EPS. The company’s quarterly revenue was down 14.1% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. As a group, research analysts anticipate that ICU Medical, Inc. will post 4.11 EPS for the current year.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.